VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 404 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2016. The put-call ratio across all filers is 0.94 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2016 | $7,536,000 | +21.9% | 306,966 | 0.0% | 0.74% | +12.9% |
Q2 2016 | $6,182,000 | -23.8% | 306,966 | -0.6% | 0.65% | -19.4% |
Q1 2016 | $8,118,000 | -93.0% | 308,666 | -72.8% | 0.81% | -90.6% |
Q4 2015 | $115,530,000 | -53.0% | 1,136,554 | -17.5% | 8.56% | -36.6% |
Q3 2015 | $245,827,000 | -18.7% | 1,378,108 | +1.3% | 13.50% | -12.2% |
Q2 2015 | $302,291,000 | +69.5% | 1,360,752 | +51.5% | 15.37% | +39.2% |
Q1 2015 | $178,356,000 | +40.0% | 897,976 | +0.8% | 11.04% | +22.4% |
Q4 2014 | $127,429,000 | -2.5% | 890,426 | 0.0% | 9.02% | -6.6% |
Q3 2014 | $130,670,000 | +20.2% | 890,426 | +3.3% | 9.66% | +7.7% |
Q2 2014 | $108,745,000 | +8.0% | 862,236 | +24.4% | 8.97% | +10.8% |
Q1 2014 | $100,703,000 | +23.7% | 693,381 | 0.0% | 8.09% | +16.0% |
Q4 2013 | $81,403,000 | +15.0% | 693,381 | +2.2% | 6.98% | -7.3% |
Q3 2013 | $70,811,000 | +112.9% | 678,719 | +75.7% | 7.53% | +84.2% |
Q2 2013 | $33,253,000 | – | 386,300 | – | 4.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |